Free cash flow oscillated around breakeven, reaching -$20.7M in 2026Q3 after $11.7M in 2026Q2, with working capital drains of -$28.0M in the latest quarter weighing on cash conversion.
NeoGenomics, Inc. (NEO) cash flow statement — 26-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 |
|---|
| Cash from Operations | 4.28M | 5.23M | 7.02M | -1.95M | -65.99M | -26.72M | 1.46M | 23.37M | 44.79M | 18.04M | 21.48M | 6.39M | 9.45M | 2.23M | -492K | 69K | -2.05M | -1.5M | -138.31K | -2.64M | -693.78K | -902.05K | -658.13K | -532.37K | -384.8K | -77.41K | -177.13K |
| Operating CF Margin % | - | 0.72% | 1.06% | -0.33% | -12.95% | -5.52% | 0.33% | 5.72% | 16.18% | 7.51% | 8.8% | 6.41% | 10.85% | 3.35% | -0.82% | 0.16% | -5.97% | -5.09% | -0.69% | -22.97% | -10.71% | -47.85% | -117.93% | -143.89% | -411.59% | -7740.7% | -70.18% |
| Operating CF Growth % | -220.26% | -25.53% | 459.6% | 97.04% | -146.95% | -1930.34% | -93.75% | -47.82% | 148.3% | -16.02% | 235.95% | -32.35% | 324.34% | 552.64% | -813.04% | 103.36% | -36.76% | -984.85% | 94.77% | -280.9% | 23.09% | -37.06% | -23.62% | -38.35% | -397.11% | 56.3% | - |
| Net Income | -32.3M | -108.03M | -78.73M | -87.97M | -144.25M | -8.35M | 4.17M | 8.01M | 2.64M | -846K | -5.72M | -2.54M | 1.13M | 2.03M | 65K | -1.18M | -3.3M | -2.24M | -1.38M | -3.38M | -129.66K | -997.16K | -818.99K | -535.76K | -590.52K | -8.08M | -970.28K |
| Depreciation & Amortization | 65.21M | 67.82M | 72.55M | 72.58M | 69.43M | 53.35M | 35.72M | 30.27M | 21.73M | 22.59M | 23.21M | 7.14M | 5.64M | 4.41M | 3.82M | 2.08M | 1.78M | 1.18M | 740.56K | 506.36K | 306.59K | 181.07K | 104.26K | 48.04K | -207.31K | 245.67K | 26.4K |
| Stock-Based Compensation | 26.69M | 41.32M | 33.41M | 24.63M | 24.67M | 22.46M | 10.21M | 10M | 6.96M | 6.44M | 5.44M | 3.48M | 692K | 929K | 798K | 458K | 411K | 372.95K | 246.18K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes | -1.35M | 0 | 0 | 0 | -16.1M | 0 | 951K | 1.49M | 404K | 19.96M | 15.32M | -2.07M | 2.44M | 2.8M | 3.05M | 0 | 49K | 68.65K | 254.01K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 12.86M | 36.21M | 12.42M | 14.29M | 31.95M | -89.59M | 12.15M | 6.03M | 542K | 440K | 4.6M | 2.32M | 66K | 49K | 38K | 2.61M | 2.46M | 2.22M | 1.93M | 1.41M | 628.84K | 298.09K | 35.18K | 46.72K | 236.3K | 7.74M | 195.24K |
| Working Capital Changes | -66.83M | -32.09M | -32.63M | -25.49M | -31.7M | -4.6M | -61.75M | -32.42M | 12.51M | -30.55M | -21.36M | -1.95M | -517K | -7.99M | -8.26M | -3.9M | -3.45M | -3.11M | -1.93M | -1.18M | -1.5M | -384.04K | 21.41K | -91.36K | 176.74K | 13.39K | 571.51K |
| Change in Receivables | -58.38M | -6.18M | -19.31M | -11.52M | -7.58M | -4.69M | -12.6M | -17.3M | 209K | -24.24M | -18.43M | -3.21M | -2.77M | -7.42M | -9.19M | -5.23M | -2.86M | -3.87M | -1.47M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 3.04M | -1.54M | -2.7M | -454K | -1.1M | 1.63M | -15.2M | -5.75M | 734K | -1.42M | -1.15M | -896K | -229K | -442K | -657K | -315K | -285K | -110.34K | -186.71K | -187.39K | -57.36K | -44.88K | -4.53K | 8.71K | -19.31K | 0 | 0 |
| Change in Payables | -6.58M | -4.69M | -4M | -4.55M | 2.79M | 19.32M | -3.97M | -9M | 12.92M | -4.54M | -2.1M | 5.9M | 2.47M | 868K | 1.44M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | -31.47M | -12.34M | 12.86M | 76.71M | 517K | -632.37M | -159.44M | -19.63M | -139.69M | -13.69M | -6.5M | -75.16M | -9.6M | -2.01M | -3.65M | -897K | -916K | -963.74K | -501.78K | -716.14K | -398.62K | -117.63K | -85.93K | -63.19K | -418K | -2.69K | 0 |
| Capital Expenditures | -32.86M | -27.01M | -41.06M | -28.75M | -30.89M | -64.14M | -29.1M | -20.03M | -14.31M | -13.69M | -7.54M | -2.21M | -3.77M | -2.01M | -3.65M | -897K | -916K | -963.74K | -501.78K | -516.14K | -398.62K | -117.63K | -85.93K | -63.19K | -418K | -2.9K | 0 |
| CapEx % of Revenue | 4.17% | 3.71% | 6.22% | 4.86% | 6.06% | 13.24% | 6.55% | 4.9% | 5.17% | 5.7% | 3.09% | 2.22% | 4.33% | 3.03% | 6.1% | 2.06% | 2.67% | 3.27% | 2.51% | 4.49% | 6.16% | 6.24% | 15.4% | 17.08% | 447.1% | 290% | - |
| Acquisitions | 0 | -6.45M | 0 | 0 | 0 | -419.4M | -37M | 399K | -125.38M | 0 | 1.03M | -72.94M | -5.83M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 1.47M | 1.57M | 0 | 0 | 12.1M | -15M | 0 | 0 | 0 | 0 | 1.03M | -72.94M | -9.6B | -2.01M | -1.04M | -897M | -916M | -963.74K | 0 | -200K | 0 | 0 | 0 | 0 | 0 | 209 | 0 |
| Cash from Financing | 2.32M | -200.29M | 4.65M | 4.55M | 11.83M | 725.28M | 235.6M | 159.47M | 91.96M | -4.09M | -25.87M | 58.49M | 29.01M | 2.75M | 3.38M | 2.36M | 2.43M | 3.63M | 897.68K | 3.44M | 1.21M | 918.08K | 831.56K | 620.61K | 725.58K | 157.31K | 133.7K |
| Debt Issued (Net) | 16.87M | -201.25M | 0 | -70K | -758K | 334.41M | 91.31M | -12.51M | 5.1M | -6.68M | 27.56M | 60.91M | -7.86M | -2.61M | 2.37M | -1.12M | 1.75M | -1.13M | 837.21K | -168.48K | 118.02K | 0 | 0 | 0 | 0 | 0 | -5.87K |
| Equity Issued (Net) | -5.55M | 962K | 4.65M | 4.62M | 12.59M | 423.21M | 147.6M | 171.98M | 94M | 2.59M | -51.23M | 0 | 34.25M | 0 | 0 | 3.48M | 180K | 5.76M | 60.48K | 5.29M | 1.09M | 211.66K | 740.23K | 0 | 0 | 0 | 25K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -22.69M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -50.1M | 0 | -55M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -8.99M | 0 | 0 | 0 | 0 | -32.34M | -3.32M | 0 | -7.14M | 0 | -2.2M | -2.42M | 2.62M | 5.36M | 1.01M | 0 | 500K | -1M | 0 | -1.68M | 0 | 706.41K | 91.33K | 620.61K | 725.58K | 157.31K | 114.57K |
| Net Change in Cash | -24.84M | -207.39M | 24.52M | 79.31M | -53.65M | 66.19M | 77.62M | 163.21M | -3.01M | 296K | -10.89M | -10.27M | 28.86M | 2.97M | -760K | 1.53M | -534K | 1.16M | 257.6K | 84.31K | 115.32K | -101.6K | 87.5K | 25.05K | -77.22K | 77.22K | -43.43K |
| Free Cash Flow | -28.58M | -21.78M | -34.04M | -30.7M | -96.88M | -90.86M | -27.64M | 3.34M | 30.48M | 4.35M | 13.94M | 4.18M | 5.68M | 216K | -4.14M | -828K | -2.97M | -2.46M | -640.09K | -3.16M | -1.09M | -1.02M | -744.07K | -595.55K | -802.79K | -80.31K | -177.13K |
| FCF Margin % | -3.63% | -2.99% | -5.15% | -5.19% | -19.01% | -18.76% | -6.22% | 0.82% | 11.01% | 1.81% | 5.71% | 4.19% | 6.52% | 0.33% | -6.92% | -1.9% | -8.64% | -8.36% | -3.2% | -27.46% | -16.87% | -54.09% | -133.33% | -160.97% | -858.69% | -8030.7% | -70.18% |
| FCF Growth % | -67.65% | 36.02% | -10.85% | 68.31% | -6.62% | -228.79% | -927.43% | -89.04% | 601.08% | -68.82% | 233.68% | -26.42% | 2528.7% | 105.21% | -400.48% | 72.1% | -20.45% | -284.97% | 79.74% | -189.16% | -7.13% | -37.04% | -24.94% | 25.81% | -899.66% | 54.66% | - |
| FCF per Share | -0.22 | -0.17 | -0.27 | -0.24 | -0.78 | -0.76 | -0.25 | 0.03 | 0.33 | 0.05 | 0.18 | 0.35 | 0.51 | 0.02 | -0.43 | -0.10 | -0.40 | -0.36 | -0.10 | -0.50 | -0.21 | -0.23 | -0.18 | -0.21 | -0.94 | -0.11 | -1.13 |
| FCF Conversion (FCF/Net Income) | 0.89x | -0.05x | -0.09x | 0.02x | 0.46x | 3.20x | 0.35x | 2.92x | 16.96x | -45.55x | -3.50x | -2.52x | 8.35x | 1.10x | -7.57x | -0.06x | 0.62x | 0.67x | 0.10x | 0.78x | 5.34x | 0.90x | 0.80x | 0.99x | 0.65x | 0.01x | 0.18x |
| Interest Paid | 97K | 0 | 3.83M | 3.38M | 3.4M | 3.06M | 2.93M | 4.78M | 0 | 5.16M | 5.42M | 911K | 981K | 945K | 0 | 0 | 661K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 207K | 175K | 180K | 148K | 246K | 319K | 0 | 284K | 290K | 25K | 177K | 17K | 0 | 0 | 15K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying NEO stock.
NeoGenomics, Inc. (NEO) generated $5.2M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
NeoGenomics, Inc. (NEO) reported negative free cash flow of $21.8M in 2025, indicating capital requirements exceeded cash from operations.
NeoGenomics, Inc. (NEO) spent $27.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
Key Metrics
Top Statement Risk
Volatile quarterly cash generation
Metrics are mathematically derived from official filings.
Cash Conversion Swings With Working Capital
Based on NEO's reported figures, operating cash flow ranged from -$25.3M to +$20.3M across the ten quarters, with OCF/NI ratios distorted by near-zero or negative net income denominators.
The OCF/NI ratio is largely uninterpretable here because net income was negative in most quarters, so the relationship between reported earnings and cash generation cannot be cleanly read from the ratio alone. The more informative pattern is that operating cash flow turned positive in several quarters even while GAAP net losses persisted, which suggests non-cash charges such as the $16M to $18M quarterly D&A and $8M to $12M SBC are carrying much of the earnings gap. Investors should monitor whether working capital swings, such as the -$28.0M change in 2026Q3, continue to drive quarterly OCF volatility.
Free Cash Flow Oscillates Around Breakeven
As reported in NEO's cash flow statements, free cash flow alternated between small positives and negatives, reaching $14.0M in 2025Q2 and -$29.8M in 2025Q1, with FCF margins spanning -17.8% to +7.7%.
The FCF profile shows no durable upward trajectory, with the strongest quarter, 2025Q2, appearing to reflect a favorable working capital inflow rather than a structural improvement in earnings power. Several quarters near zero FCF margin suggest the business is roughly self-funding at the operating line but has not yet demonstrated consistent surplus generation. This pattern warrants further investigation into whether recent quarterly gains are repeatable.
Capital Intensity Declining but Persistent
According to reported figures, CapEx as a share of revenue fell from 8.0% in 2024Q2 to 2.7% in 2026Q1 and 2.7% in 2025Q1, while D&A remained near $16M to $18M per quarter.
Capex intensity appears to have moderated substantially from the mid-2024 peak, which may indicate a shift from facility buildout toward a more maintenance-oriented spending profile. However, D&A running well above CapEx in recent quarters suggests the asset base is being depreciated faster than it is being replaced, a dynamic that could flatter near-term cash flow if sustained. Investors should monitor whether capex remains below depreciation over subsequent periods.
Working Capital Drains Dominate Recent Quarters
As reported in NEO's cash flow data, working capital consumed cash in most recent quarters, including -$28.0M in 2026Q3, -$19.2M in 2026Q1, and -$30.2M in 2025Q1, while releasing $14.0M in 2025Q2.
The recurring working capital outflows are the single largest driver of quarterly cash volatility and may indicate receivable build or inventory accumulation that is not yet reflected in earnings quality. Because the reported data does not break out receivables, inventory, and payables separately, the specific source of these drains cannot be confirmed from the supplied figures. Investors should monitor collection trends in future filings to assess whether these outflows reflect timing or a persistent cash absorption.
Cumulative Cash Gap Versus Reported Losses
Based on NEO's reported figures, cumulative net losses over the ten quarters total roughly -$196M, while cumulative operating cash flow is approximately -$6M, a gap of roughly $190M attributable largely to non-cash items.
The cumulative divergence suggests that the reported losses overstate the cash consumption of the operating business, with D&A and SBC accounting for a substantial portion of the difference over the period. This pattern may indicate that the business is closer to cash breakeven than its GAAP results imply, though the reliance on non-cash add-backs means the economic cost of equity compensation should not be ignored. Investors should monitor whether this gap narrows as operating losses shrink.
Non-Cash Add-Backs May Flatter Cash View
Based on reported figures, NEO's cash flow picture relies heavily on roughly $16M to $18M of quarterly D&A and recurring SBC, which may overstate underlying cash generation if these add-backs are treated as costless.
Stock-based compensation is added back in operating cash flow, yet it represents a real economic cost to shareholders through dilution, so a cash breakeven reading may understate the true cost of running the business. The quarterly D&A add-back is similarly large relative to reported capex, which suggests the cash profile could look better than the economic reinvestment need if the asset base requires replacement at higher cost over time. Investors should monitor whether operating cash flow remains positive once SBC and maintenance capex are considered together.